Search
Myriad Genetics Inc
MYGNAdd to Watchlist
4.140USD
+0.130+3.24%
Close 09-24 16:00（ET）
391.02MMarket Cap
LossP/E TTM
About Myriad Genetics Inc Company
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Myriad Genetics Inc Profile
Ticker SymbolMYGN
Company nameMyriad Genetics Inc
IPO dateOct 06, 1995
CEORaha (Samraat S)
Number of employees2700
Security typeOrdinary Share
Fiscal year-endOct 06
Address322 North 2200 West
CitySALT LAKE CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code84116
Phone18015843600
Websitehttps://myriad.com/
Ticker SymbolMYGN
IPO dateOct 06, 1995
CEORaha (Samraat S)
Company Executives of Myriad Genetics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer
Chief Operating Officer
296.53K
-58.32%
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer
Chief Operating Officer
296.53K
-58.32%
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer
Chief Operating Officer
296.53K
-58.32%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Mr. Raj Jampa
Mr. Raj Jampa
Chief Technology Officer
Chief Technology Officer
251.89K
--
Mr. Raj Jampa
Mr. Raj Jampa
Chief Technology Officer
Chief Technology Officer
251.89K
--
Mr. Raj Jampa
Mr. Raj Jampa
Chief Technology Officer
Chief Technology Officer
251.89K
--
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
191.84K
+31.12%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer
Chief Operating Officer
296.53K
-58.32%
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer
Chief Operating Officer
296.53K
-58.32%
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer
Chief Operating Officer
296.53K
-58.32%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
FAQs
Who are the top five shareholders of Myriad Genetics Inc?
The top five shareholders of Myriad Genetics Inc are: Mr. Mark S. Verratti
How many institutions hold shares of Myriad Genetics Inc (MYGN)?
As of 2026Q1, 539 institutions hold shares of Myriad Genetics Inc, with a combined market value of approximately 102.95M, accounting for 109.00% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -7290509.00.
What is the biggest source of revenue for Myriad Genetics Inc?
In 2026Q1, the Hereditary Cancer business generated the highest revenue for Myriad Genetics Inc, amounting to 114.10M and accounting for 59.83% of total revenue.